RLMD — Relmada Therapeutics, Inc.
$3.27-0.61%
Last close: · regular session
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for RLMD in the TickerWise workspace.
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 17
- Website: https://www.relmada.com
Latest SEC filings for RLMD
Latest RLMD news
- Relmada Therapeutics, Inc. (NASDAQ:RLMD) Stock Has Consensus Target Price of $12.00 Read article
- 812,059 Shares in Relmada Therapeutics, Inc. $RLMD Purchased by Bank of America Corp DE Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.